Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events "DECLARE-TIMI58"

Active, not recruiting

Phase 3 Results N/A

Summary of Purpose

This study is being carried out to determine the effect of dapagliflozin on cardiovacular outcomes when added to current background therapy in patients with type 2 diabetes with either established cardiovacular disease or cardiovascular risk factors.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 26 March 2018.

25 Apr 2013 15 Nov 2012 18 Jul 2018 18 Jul 2018 1 Mar 2018 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety Study
  • Intervention: Parallel Assignment